
Fig. 1


PPMX2016
(Mouse)
100
75
50
25
0
Percent of inhibition (%)
1.1 uM
0.001
0.01
0.1
1
10
100
Antibody temperature (μg/mL)



PPAT-052-27c
(Chimera)
100
75
50
25
0
Percent of inhibition (%)
1.1 uM
0.001
0.01
0.1
1
10
100
1000
Antibody temperature (μg/mL)

Fig. 2



PPMX2016 (antibody : chelating agent 1:10) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Spleen
Pancreas
Kidneys
Stomach
Small Intestine
Large intestine
Muscle
Bone
Skin
Tumor

Fig. 3



PPMX2016 (antibody : chelating agent 1:3) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Pancreas
Spleen
Kidneys
Small Intestine
Large intestine
Muscle
Bone
Tumor

Fig. 4



PPMX2029 (antibody : chelating agent 1:10) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Spleen
Pancreas
Kidneys
Stomach
Small Intestine
Large intestine
Muscle
Bone
Skin
Tumor

Fig. 5



PPMX2029 (antibody : chelating agent 1:3) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Pancreas
Spleen
Kidneys
Small Intestine
Large intestine
Muscle
Bone
Tumor

Fig. 6



PPMX2025 (antibody : chelating agent 1:10) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Spleen
Pancreas
Kidneys
Stomach
Small Intestine
Large intestine
Muscle
Bone
Skin
Tumor

Fig. 7



PPMX2025 (antibody : chelating agent 1:3) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Pancreas
Spleen
Kidneys
Small Intestine
Large intestine
Muscle
Bone
Tumor

Fig. 8




Fig. 9



PPAT-052-27c (antibody : chelating agent 1:3) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Pancreas
Spleen
Kidneys
Small Intestine
Large intestine
Muscle
Bone
Tumor

Fig. 10



PPAT-052-27c (antibody : chelating agent 1:3) 48 hours after administration
%ID/g
60
50
40
30
20
10
0
Blood
Liver
Spleen
Kidney
Bone
Tumor

Fig. 11



PPAT-052-28c (antibody : chelating agent 1:3)
%ID/g
60
50
40
30
20
10
0
Blood
Liver
Spleen
Kidney
Bone
Tumor
48 hours after administration
96 hours after administration

Fig.12



NCI-H358 xenograft growth
Tumor volume (mm3)
1400
1200
1000
800
600
400
200
0
0
10
20
30
40
50
60
Days after treatment
Saline
PPMX2029-200 μCi
PPMX2029-150 μCi
PPMX2029-100 μCi
PPMX2029-50 μCi
PPMX2029

Fig. 13




NCI-H1373 xenograft growth
Tumor Volume(mm3)
3000
2500
2000
1500
1000
500
0
0
5
10
15
20
25
30
Days after treatment
PPAT-052-27c 150 μci
PPAT-052-27c 100 μci
PPAT-052-27c
Saline

Fig. 14


negative control
anti-CDH3 antibody
Lung cancer
Lung cancer
Colorectal cancer
Colorectal cancer
Pancreatic cancer